Hambro Perks Special Opportunities .
Hambro Perks Special Opportunities Fund invests in US and UK high-growth technology companies. The portfolio currently comprises 11 privately held stakes in companies operating in healthcare, biotechnology and life sciences, including:
Gelesis – Gelesis is a biotechnology company developing a novel category of therapies for GI-related chronic diseases. The Gelesis portfolio includes a product for obesity, and a pipeline with potential therapies for Non-alcoholic Fatty Liver Disease and Type 2 diabetes.
Vedanta – Vedanta Bioscience is developing a new category of therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria. It has four clinical-stage programs in development for solid tumors, high-risk CDI, food allergy, and IBD, and one preclinical discovery program for the prevention of infection and recurrence of several multi-drug resistant organisms.
Nexeon – Nexeon is a British business developing silicon anode battery technology to reduce carbon anode energy inefficiency. Nexeon’s technology makes a big difference to the real world performance of battery operated equipment, improving productivity and quality of life.